News Release Detail
December 23, 2004
Mylan Receives Approval for Quinapril Tablets, USP
Mylan Receives Approval for Quinapril Tablets, USP
Mylan Receives Approval for Quinapril Tablets, USPPITTSBURGH, Dec. 23 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc.
(NYSE: MYL) today announced that the U.S. Food and Drug Administration has
granted approval for Mylan Pharmaceuticals Inc.'s Abbreviated New Drug
Application for Quinapril Tablets USP, 5 mg, 10 mg, 20 mg, and 40 mg.
Quinapril Tablets are the generic version of Pfizer Pharmaceuticals'
Accupril® Tablets.
Mylan Laboratories Inc. is a leading pharmaceutical company with four subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc., UDL Laboratories, Inc. and Mylan Bertek Pharmaceuticals Inc., that develop, license, manufacture, market and distribute an extensive line of generic and proprietary products.
For more information about Mylan, visit www.mylan.com.
SOURCE Mylan Laboratories Inc.
12/23/2004
CONTACT: Media, Heather Bresch, or Investors, Kris King, both of Mylan
Laboratories Inc., +1-724-514-1800
Web site: http://www.mylan.com